- Home
- KBDC vs APLT Comparison
KBDC vs APLT Comparison
Compare KBDC & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBDC
- APLT
- Stock Information
- Founded
- KBDC 2021
- APLT 2016
- Country
- KBDC United States
- APLT United States
- Employees
- KBDC N/A
- APLT N/A
- Industry
- KBDC
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- KBDC
- APLT Health Care
- Exchange
- KBDC Nasdaq
- APLT Nasdaq
- Market Cap
- KBDC 1.1B
- APLT 971.6M
- IPO Year
- KBDC N/A
- APLT 2019
- Fundamental
- Price
- KBDC $16.62
- APLT $8.69
- Analyst Decision
- KBDC Buy
- APLT Strong Buy
- Analyst Count
- KBDC 5
- APLT 5
- Target Price
- KBDC $17.10
- APLT $12.50
- AVG Volume (30 Days)
- KBDC 31.7K
- APLT 1.8M
- Earning Date
- KBDC 11-13-2024
- APLT 11-07-2024
- Dividend Yield
- KBDC 2.40%
- APLT N/A
- EPS Growth
- KBDC N/A
- APLT N/A
- EPS
- KBDC N/A
- APLT N/A
- Revenue
- KBDC N/A
- APLT N/A
- Revenue This Year
- KBDC $164.31
- APLT N/A
- Revenue Next Year
- KBDC $16.04
- APLT $3,169.03
- P/E Ratio
- KBDC N/A
- APLT N/A
- Revenue Growth
- KBDC N/A
- APLT N/A
- 52 Week Low
- KBDC $15.69
- APLT $1.79
- 52 Week High
- KBDC $16.80
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- KBDC N/A
- APLT 46.34
- Support Level
- KBDC N/A
- APLT $9.44
- Resistance Level
- KBDC N/A
- APLT $10.62
- Average True Range (ATR)
- KBDC 0.00
- APLT 0.62
- MACD
- KBDC 0.00
- APLT -0.13
- Stochastic Oscillator
- KBDC 0.00
- APLT 14.95
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.